Imagine a slow-burning fuse that eventually leads to a serious blood cancer. This work looks at the early stages of that fuse to find the exact molecular 'triggers' that make the disease accelerate. By combining lifestyle data with deep biological scans, the goal is to stop the cancer before it even starts.
Multiple Myeloma is incurable once it develops resistance to therapy. There is a critical lack of tools to identify which patients in the pre-cancerous stage will actually progress to active disease.
A molecular model of cellular processes and a comprehensive dataset integrating omics, lifestyle, and clinical data from thousands of patients.
If you are a drug discovery firm dealing with high failure rates in late-stage cancer trials — this project developed molecular models of cellular processes that identify new targets to prevent progression from MGUS to active MM.
If you are a precision medicine lab dealing with the lack of early biomarkers — this project developed clinically actionable molecular features that allow for personalized diagnosis and prevention for the 3-5% of the ageing population with MGUS.
If you are a bioinformatics software provider dealing with fragmented patient data — this project developed an integrated system combining omics, lifestyle, and clinical datasets to create patient-specific profiles.
Based on available project data, there is no pricing information provided as the project is currently in the research and data collection phase.
The project uses a systems medicine approach with samples from several thousand patients, suggesting the data foundation is scalable for industrial diagnostic development.
Based on available project data, specific IP or licensing agreements are not listed, though the project involves 4 industry partners who typically manage such transitions.
The project aims to yield clinically actionable molecular features that can be integrated into patient management to improve personalized diagnosis and prevention.
The project period runs from 2023-01-01 to 2026-12-31, meaning final results and potential commercial tools will be available toward the end of 2026.
The consortium is well-balanced for commercial transition, featuring a 29% industry ratio with 4 companies (including 2 SMEs) working alongside 7 universities and 3 research institutes. This mix of academic depth and industrial presence across 6 countries suggests a strong pipeline for moving research findings into commercial diagnostic or therapeutic products.
Contact the National and Kapodistrian University of Athens
Contact us to bridge the gap between these molecular models and your product pipeline.
